Nathalie Britzen-Laurent
Overview
Explore the profile of Nathalie Britzen-Laurent including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
666
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang S, Yun D, Yang H, Eckstein M, Daw Elbait G, Zhou Y, et al.
Cell Death Discov
. 2024 Mar;
10(1):124.
PMID: 38461159
Pancreatic cancer is a malignant tumor of the digestive system. It is highly aggressive, easily metastasizes, and extremely difficult to treat. This study aimed to analyze the genes that might...
2.
Zhang J, Zhang S, Dorflein I, Ren X, Pfeffer S, Britzen-Laurent N, et al.
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835536
Pancreatic cancer is among the cancers with the highest mortality rates. Most of the patients are found to have advanced cancer, losing the chance of surgical treatment, and there is...
3.
Thoma O, Naschberger E, Kubankova M, Larafa I, Kramer V, Menchicchi B, et al.
Gastroenterology
. 2023 Sep;
166(2):284-297.e11.
PMID: 37734420
Background & Aims: T cells are crucial for the antitumor response against colorectal cancer (CRC). T-cell reactivity to CRC is nevertheless limited by T-cell exhaustion. However, molecular mechanisms regulating T-cell...
4.
Naschberger E, Flierl C, Huang J, Erkert L, Gamez-Belmonte R, Gonzalez-Acera M, et al.
Front Cell Dev Biol
. 2023 Aug;
11:1213383.
PMID: 37645250
The development of inflammatory bowel diseases (IBD) involves the breakdown of two barriers: the epithelial barrier and the gut-vascular barrier (GVB). The destabilization of each barrier can promote initiation and...
5.
Britzen-Laurent N, Weidinger C, Sturzl M
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982601
Inflammatory bowel diseases (IBDs) consist of a group of chronic inflammatory disorders with a complex etiology, which represent a clinical challenge due to their often therapy-refractory nature. In IBD, inflammation...
6.
He H, Zhang S, Yang H, Xu P, Kutschick I, Pfeffer S, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612240
Liver metastasis occurs frequently in patients with pancreatic cancer. We analyzed the molecular profiling in liver metastatic lesions aiming to uncover novel genes responsible for tumor progression. Bioinformatics analysis was...
7.
Krug J, Rodrian G, Petter K, Yang H, Khoziainova S, Guo W, et al.
Gastroenterology
. 2022 Nov;
164(3):392-406.e5.
PMID: 36402190
Background & Aims: Advanced colorectal carcinoma (CRC) is characterized by a high frequency of primary immune evasion and refractoriness to immunotherapy. Given the importance of interferon (IFN)-γ in CRC immunosurveillance,...
8.
Yun D, Yang Z, Zhang S, Yang H, Liu D, Grutzmann R, et al.
Front Cell Dev Biol
. 2022 Sep;
10:975684.
PMID: 36060802
Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive digestive malignancy due to frequent late-stage diagnosis, rapid progression and resistance to therapy. With increasing PDAC incidence worldwide, there is an urgent...
9.
Zeng S, Lan B, Ren X, Zhang S, Schreyer D, Eckstein M, et al.
J Exp Clin Cancer Res
. 2022 Aug;
41(1):241.
PMID: 35945614
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a dismal prognosis. Although combined treatment with gemcitabine and albumin-bound paclitaxel has improved the prognosis of PDAC, both intrinsic and...
10.
Yang H, Liu B, Liu D, Yang Z, Zhang S, Xu P, et al.
Cancers (Basel)
. 2022 Jul;
14(13).
PMID: 35804923
Pancreatic cancer is one of the most lethal cancers. Due to the difficulty of early diagnosis, most patients are diagnosed with metastasis or advanced-stage cancer, limiting the possibility of surgical...